Comparison of 10-Day Course of Triple Therapy Versus 14-Day Course for Eradication of Helicobacter pylori Infection in an Indonesian Population: Double-Blinded Randomized Clinical Trial

Ryan Herardi1, Ari Fahrial Syam2*, Marcellus Simadibrata3, Siti Setiati3, Nikko Darnindro4, Murdani Abdullah5, Dadang Makmun3

Abstract

Objective: The aim of this study was to compare the effectiveness of 10-day course of triple therapy versus a 14-day course in the treatment of H. pylori infection in an Indonesian population. Methods: A double-blind randomized clinical trial was included patients, Indonesian population, with H. pylori infection conducted in Cipto Mangunkusumo Hospital, Jakarta; Cilincing District General Hospital, Jakarta; and West Nusa Tenggara General Hospital, Mataram, during October 2016 - April 2017. Patients were randomized to be given triple therapy as Rabeprazole 20 mg, Amoxicillin 1,000 mg, and Clarithromycin 500 mg twice daily, for 14 days or 10 days plus 4 days placebo. Eradication was evaluated with UBT at least 4 weeks after completion the therapy. Results: A total of 75 patients (38 in the 14-day group and 37 in the 10-day group) were included to the study. In the intention-to-threat analysis, eradication rate was 67.6% (95% CI. 52.5%-82.6%) for the 10-day group versus 86.8% (95% CI. 76.0%-97.5%) for the 14-day group (p = 0.046), whereas per protocol analysis obtained 73.5% (95% CI. 58.6%-88.3%) for the 10-day versus 91.9% (95% CI. 84.1%-99.6%) in the 14-day group (p = 0.039). Adverse events were not significantly different between the two groups. Conclusion: A 14-day course was more effective than 10-day course of triple therapy as first-line for eradication of H. pylori infection in an Indonesian population.

Keywords: Helicobacter pylori- duration- triple therapy- eradication- Indonesian population

Introduction

Helicobacter pylori (H. pylori) infects a large proportion of the world’s population. Most affected individuals are asymptomatic. However, 15-20% of the case will be related peptic ulcers and 1-4% will grow as gastric malignancy. The eradication of H. pylori infection is one of the successful keys of peptic ulcer therapy and prevention of gastric malignancy. (Atherton and Blaser, 2013).

Nowadays, American College of Gastroenterology (ACG), Asia Pacific of Gastroenterology (APAGE), World Gastroenterology Organization (WGO), and The Indonesian Society of Gastroenterology (Perkumpulan Gastroenterologi Indonesia / PGI) recommend triple therapy, consist of proton pump inhibitor, Amoxicillin, and Clarithromycin, for the first-line therapy of H. pylori infection. Yet, questions remain regarding the optimal duration of triple therapy. For Asia, APAGE and PGI recommend triple therapy for 7-14 days. (Chey and Wong, 2007; Fock et al., 2009; Hunt et al., 2010; Syam et al., 2017).

Successfulness of H. pylori eradication with the 7-day course triple therapy is declining. A Meta-analysis by Li et al., (2015) showed that longer than 7-day triple therapy course generates 73% eradication rate, while 10-to-14-day course generates 81%. Other meta-analysis conducted by Yuan et al, (2013) also indicated that the prolonging therapy is related with better eradications rates, whereas proportion of eradication rates of the 7-day, 10-day and 14-day course triple therapies were 76%, 80% and 86%.

Studies comparing directly between 10-day and 14-day course of triple therapy were limited and debatable. A study by Fennerty et al., (1998), obtained different eradication rates of H.pylori infection between two groups, 82.7% for 14-day course versus 76.9% for 10-day course. Other studies indicated that 10-day and 14-day triple therapy eradicate H. pylori infection in 80% and 77% of cases, respectively. (Chey and Wong, 2007; Fock et al., 2009; Hunt et al., 2010; Syam et al., 2017).

Another study by Chen and Falloon (2015), obtained different eradication rates of H.pylori infection between two groups, 82.7% for 14-day course versus 76.9% for 10-day course. Other studies indicated that 10-day and 14-day triple therapy eradicate H. pylori infection in 80% and 77% of cases, respectively. (Chey and Wong, 2007; Fock et al., 2009; Hunt et al., 2010; Syam et al., 2017).
and 45.2% for 10-day course. Thus, this study compares the effectiveness between 10-day course and 14-day course triple therapy in eradication of \( \text{H.pylori} \) infection in an Indonesian population.

**Materials and Methods**

**Study subjects and Materials**

A prospective double-blinded randomized clinical trial was conducted from October 2016 to June 2017 in Cipto Mangunkusumo Hospital, Jakarta; Citilincing District General Hospital, Jakarta; and West Nusa Tenggara General Hospital, Mataram, Indonesia. The following criteria applied to the patients to be admitted to the study: Indonesian people, aged over 18 years, signed informed consent, and positive for Helicobacter \( \text{pylori} \) infection from UBT or histopathology biopsy from esophagoduodenoscopy. We excluded patients who had previous \( \text{H.pylori} \) therapy, abnormal ALT, arrhythmia, prolonged QT, and pregnant or breastfeeding woman.

According to the two independent sample size formula as follows

with the proportion 63.6% and expected proportion 91.4% (from previous studies), we obtained that minimum sample is 34 patients for each group.

Patients did not use proton pump inhibitor or antibiotics for 2 weeks before UBT or esophagoduodenoscopy. Patients with positive results were randomized using Microsoft Excell 2015 ®, into either group A or group B. Patients and physicians did not know where the patients were given triple therapy as Rabeprazole 20 mg, Amoxicillin 1,000 mg, and Clarithromycin 500 mg twice daily for 14 days or Rabeprazole 20 mg, Amoxicillin 1,000 mg, and Clarithromycin 500 mg twice daily 10 days plus 4 days placebo. Only the pharmacist knew. We also documented patients’ demographics (sex, age, ethnic, level of education, and salary), smoking habits, nutritional status, and comorbid disease. Patients’ sex and age were based on their ID Card at the time the study was done. Patients’ ethnic was asked to them (Javanese, Sundanese, Buginese, Batak, Balinese, Betawi, Malay, and others). Level of educational was the patient’s last education (Low for not graduated or Elementary School; Medium for Junior High School or Senior High School; High : Diploma, Undergraduate, Graduate, or Post-graduate). Salary was the patient’s monthly income (Below or Above the 2016 Regional Minimum Income. The 2016 Regional Minimum Income for Jakarta was IDR 3,100,000, (about USD 235.00) per month and Mataram was IDR 1,482,950 (about USD 115.00) per month. Smoking habits was asked to the patient at the time the study was done. Nutritional status was determined by patient’s Body Mass Index (BMI) (underweight : BMI less than 18.5 kg/m²; normal : BMI 18.5-22.9 kg/m²; overweight : BMI 23.0-25.0 kg/m²; and Obesity : BMI above 25.0 kg/m²). Comorbid disease was based on medical record (Type 2 Diabetes Mellitus (DM); Hypertension; Dyslipidemia; Coronary Artery Disease; Asthma; Osteoarthritis; and other diseases).

**Research**

Patients did not use proton pump inhibitor or antibiotics. Double-blind ing and placebo control. The patients were divided into two groups. Three patients did not sign the informed consent. A total of 79 patients acquired positive \( \text{H.pylori} \) infection. Three patients did not sign the informed consent and 1 patient had history of penicillin allergic, thus 75 patients met the criteria for study. The randomized process created 38 patients in group A and 37 patients in group B. At the end of 4 patients (1 in the group A and 3 in the group B) were lost to follow up. All baseline characteristics were similar for the two treatment groups with respect to demographics (sex, age, ethnic, level of educational, and salary), smoking habits, nutritional status, and comorbid disease. Table 1 describes baseline characteristics between those two groups.

Using ITT analysis, we obtained that the group A eradication rate was 86.8% (95% CI. 75.6%-97.5%) while the group B eradication rate was 67.6% (95% CI. 52.5%-82.6%), and statistically significant (p = 0.046; Chi-Square test). The ITT analysis is described in the Table 2. Expanding PP analysis, we obtained that the group A eradication rate was 91.9% (95% CI. 84.1%-99.6%), whereas the group B eradication rate was 73.5% (95% CI. 58.6%-88.3%), and statistically significant (p = 0.039; Chi-square test). The PP analysis is depicted in the Table 3. Adverse events (taste perversion, nausea, vomiting, headache, fatigue, and diarrhea) were not significantly different between the two groups.
Asian Pacific Journal of Cancer Prevention, Vol 21

DOI:10.31557/APJCP.2020.21.1.19

Optimum Duration of Triple Therapy for Eradication Helicobacter Pylori

Discussion

The proportion of female patients were higher than other study. Kawakubo et al., (2016), showed that complaints in the upper gastrointestinal symptoms were more frequent in female than male. In both groups, the number of female patients were similar. H.pylori infected all ages, related with previous studies conducted by Goto et al., (2016) and Darnindro et al., (2015). Many studies also showed that H.pylori infection spread across all ages. Furthermore, it was uncommon to find the infection in the children who inherited the infection from their parents. We obtain comparable age between both groups.

Bugisnese and Batak were the most ethnics infected by H.pylori in this research. This finding also confirmed the findings from Goto et al., (2016) and Darnindro et al., (2015). in the previous study in Indonesia. Goto et al., (2016), noticed that eating using hand was more frequent in Bugisnese and Batak than other ethnics, thus they prone to the H.pylori infection. We found that H.pylori infection accross all of the education levels. This was related with the study from Darnindro et al., (2015), showing that H.pylori infection spreads across all education levels.

Table 1. Baseline Characteristics between Two Groups

| Variable                  | 14-day Triple Therapy (n=38) | 10-day Triple Therapy + 4-day Placebo (n=37) |
|---------------------------|------------------------------|---------------------------------------------|
| Sex; n (%)                | Male                         | 17 (44.7)                                   |
|                           | Female                       | 21 (55.3)                                   |
| Age; years                | Mean                         | 44.05 (95% CI: 39.26-48.84)                 |
|                           | (95% CI: 39.94-50.23)        |                                             |
| Classification of age; years (%) | 18-30                      | 9 (23.7)                                   |
|                           | 30-40                        | 6 (15.8)                                   |
|                           | 40-50                        | 7 (18.4)                                   |
|                           | 50-60                        | 11 (28.9)                                  |
|                           | > 60                         | 5 (13.2)                                   |
| Ethnic; n (%)             | Bugisnese                    | 11 (28.9)                                   |
|                           | Batak                        | 8 (21.1)                                   |
|                           | Javanese                     | 4 (10.5)                                   |
|                           | Betawi                       | 4 (10.5)                                   |
|                           | Sundanese                    | 3 (7.9)                                    |
|                           | Sasak                        | 3 (7.9)                                    |
|                           | Others                       | 5 (13.1)                                   |
| Level of Education; n (%) | Low                          | 9 (23.7)                                   |
|                           | Medium                       | 19 (50.0)                                  |
|                           | High                         | 10 (26.3)                                  |
| Salary / Monthly income; n (%) | Below Regional Min Income    | 24 (63.2)                                  |
|                           | Above Regional Min Income    | 14 (36.8)                                  |
| Smoking habits; n (%)     | Yes                          | 8 (21.1)                                   |
|                           | No                           | 30 (78.9)                                  |
| Nutritional Status; n (%) | Underweight                  | 5 (13.2)                                   |
|                           | Normal                       | 14 (36.8)                                  |
|                           | Overweight                   | 7 (18.4)                                   |
|                           | Obesity                      | 12 (31.6)                                  |
| Comorbid Disease; n (%)   | Type 2 DM                    | 4 (10.5)                                   |
|                           | Hypertension                 | 6 (15.8)                                   |
|                           | Dyslipidemia                 | 1 (2.6)                                    |
|                           | Coronary Artery Disease      | 2 (5.3)                                    |
|                           | Asthma                       | 1 (2.6)                                    |
|                           | Osteoarthritis               | 2 (5.3)                                    |

Table 2. Intention-to-Treat Analysis

| Research Group                  | Successful | Failed/ Lost-to-follow up |
|---------------------------------|------------|---------------------------|
| 14-day Triple Therapy (n=38)    | 33 (86.8)  | 5 (13.2)                  |
| 10-day Triple Therapy + 4-day Placebo (n=37) | 25 (67.6)  | 12 (32.4)                 |
| Total                           | 58 (77.3)  | 17 (22.7)                 |

* p, Chi-square test

Table 3. Per-Protocol Analysis

| Research Group                  | Successful | Failed |
|---------------------------------|------------|--------|
| 14-day Triple Therapy (n=37)    | 34 (91.9)  | 3 (8.1) |
| 10-day Triple Therapy + 4-day Placebo (n=34) | 25 (73.5)  | 9 (26.5) |
| Total                           | 59 (83.1)  | 12 (16.9) |

* p, Chi-square test

Table 4. Adverse Effects During Triple Therapy Given to Patients

| Adverse Effect; n (%) | 14-day Triple Therapy (n=38) | 10-day Triple Therapy + 4-day Placebo (n=37) |
|-----------------------|-------------------------------|---------------------------------------------|
| taste perversion      | 9 (23.7)                      | 7 (18.9)                                   |
| nausea                | 7 (18.9)                      | 7 (19.4)                                   |
| vomiting              | 1 (2.6)                       | 1 (2.7)                                    |
| headache              | 0 (0)                         | 1 (2.7)                                    |
| fatigue               | 2 (5.3)                       | 3 (8.1)                                    |
| diarrhea              | 0 (0)                         | 2 (5.4)                                    |

Asian Pacific Journal of Cancer Prevention, Vol 21 21

effects, we concluded that the most frequent of adverse effects is perversion taste. Patients felt flavorless taste when drinking mineral water. We find that the adverse effects between two groups tend to be the same. Table 4 reports the adverse effects.
We expected salary was a risk factor of the *H. pylori* infection. Most of our patients had monthly income below 2016 Regional Minimum Income. According to Bruce (2008), education level and monthly income were risk factors causing the *H. pylori* infection. Indeed, this hypothesis was debatable because some studies explained that low education level and low income were associated with the high proportion of *H. pylori* infection, while other studies proved no association between low education and income levels with *H. pylori* infection. Nutritional level was also considered as a success factor of *H. pylori* infection. Abdullahi et al., (2008), showed that overweight and obesity patients had lower successful for eradication of *H. pylori* infection. Our study has similar proportion of nutritional status in the both group.16,17

Smoking was an important variable in *H. pylori* infection. The study conducted by Suzuki et al., (2016), exhibited that smoking could decrease the successful for eradication of *H. pylori* infection. Our study has similar proportion of smoking in the both group. We also suggested that the patients reduced their smoking frequency during the research period (Syam et al., 2017).

With ITT analysis, we found that the eradication rate of the *H. pylori* infection in the 14-days course triple therapy was 86.6%, higher than 10-days course 67.6% (p=0.046; Chi-square test). Our finding was consistent with Chen and Fallone (2015), whereas the eradication rate of the *H. pylori* infection using 14-days course triple therapy was 82.7%, higher than 10-days course which was only 45.2%. Using per-protocol analysis, we found that the eradication rate of the *H. pylori* infection in the 14-days course triple therapy is 91.9%, higher than 10-days course triple therapy which is only 73% (p = 0.039).

Our finding in the difference is consistent with Chen and Fallone (2015), whereas the eradication rate of the *H. pylori* infection using 14-days course triple therapy is 91.5%, and 10-day course was only 63.6%. Our study is different from Chen and Fallone (2015), because our design study was double-blinded clinical trials and we have only 5.3 percent lost-to-follow up respondents, and we used Rabeprazole as proton pump inhibitor.

Fennerty et al., (1998), has different conclusion from our study. They concluded that there is no significant different between 10-day course and 14-day course triple therapy. We should note that their study was conducted 19 years ago, when the research on *H. pylori* infection had just been started and antibiots resistance were lower than nowadays. Furthermore, they used Lansoprazole as the proton pump inhibitor.

Comparing with the study from Li et al., (2015), it was clearly shown that our research was in line. We could see in their analysis demonstrating the increment of the eradication rate of the *H. pylori* infection in the prolonging triple therapy group. However, Li et al., (2015) demonstrate only 6% difference in the proportion between 14-day course and 10-day course triple therapy. This findings were thought because of very diverse ethnics, geographical locations, periods and proton pump inhibitor used in their research. Furthermore, their results were obtained from additional analysis, instead of direct comparisons between 14-day course and 10-day course triple therapy.

Our study justified recent recommendation from American College of Gastroenterology (ACG) on February 2017. ACG showed that the first line therapy that has been used and approved by United States Food and Drug Administration (FDA) was triple therapy using proton pump inhibitor, Clarithromycin 500 mg, and Amoxicillin 1,000 mg twice daily for 14 days. However, we should note that the patients had to be asked regarding their previous macrolide history and the Clarithromycin resistance was less than 15%. Therefore, APAGE and PGI
need to issue a new recommendation on the duration of triple therapy for \textit{H. pylori} infection eradication in Asia, especially in Indonesia (Chey et al., 2017).

According to the theory, the duration of triple therapy was related to the eradication rate. This was in line with previous research documenting that 3-day course and 5-day course triple therapies have been abandoned. Furthermore, 7-day course triple therapy was no longer recommended due to low eradication rate. However, we might ignore the theory because some of the determinants causing the failure for eradication of the \textit{H. pylori} infection are the antibiotics resistance and low compliance of the patient. (Chey and Wong, 2007; Fock et al., 2009; Hunt et al., 2010; Syam et al., 2017).

The bacteria could still live in the gaster that was acid by producing urease enzymes that dissolve urea becoming ammonia. The ammonia would be used to protect the bacteria from the acid. \textit{H. pylori} can be bound in all parts of gaster (fundus, antrum or corpus). If the lumen of the gaster was acid, the bacteria tent to be found in antrum area (far from antibiotics’ reach). If the gastric acid was minimized, the bacteria tent to be found in the corpus. Thus, the bacteria could be easily reached by the antibiotics (Kusters et al., 2006).

The bacteria could naturally defend themselves by transforming them from spiral to small coccoid. The small coccoid did not degenerate. Thus, this causes difficulties in the eradication. The small coccoid would be back to spiral form in the next 1-2 weeks. Therefore, the 1-2 weeks period became a good reference for the duration of triple therapy for the eradication of \textit{Helicobacter pylori} infection. If the therapy was conducted for the period equals or less than a week, the bacteria might defend themselves by the transformation process. If the therapy was conducted for the 10-day period, the drugs would attack the bacteria only in few days (and then the bacteria would remain in the remaining days). If the therapy was conducted for the 14-day period, the drugs would “fight” the bacteria in the longer period. Thus, the drugs could still attack the bacteria when the they have transformed back into original form. The clarithromycin resistance was 9.1% in Indonesia, but the prevalence of clarithromycin resistance in Java island (Jakarta is a part of Java island) was 21.4%. Thus, it was thought that triple therapy should be given with a longer duration in this population (Kusters et al., 2006; Miftahussurur et al., 2016).

In conclusion, the 14-day course was better than 10-day course triple therapy for eradication of the \textit{H. pylori} infection in an Indonesian population. There were no differences in adverse effects that occurred in both groups.

\textbf{Acknowledgements}

We gratefully thank to Directorate of Research and Community Service (Direktorat Riset dan Pengabdian Masyarakat) Universitas Indonesia for International Indexed Publications for Students’ Final Assignments Grant ( Hibah Publikasi Internasional Terindeks untuk Tugas Akhir Mahasiswa) 2016 that fund this study.

\textbf{Competing interests}

None of the authors have potential conflict of interests.

\textbf{References}

Abdullahi M, Annibale B, Capoccia D, et al (2008). The eradication of \textit{Helicobacter pylori} is affected by Body Mass Index (BMI). \textit{Obes Surg}, 18, 1450.

Atherton JC, Blaser MJ (2013). \textit{Helicobacter pylori} infections. In: Longo DL, Fauci AS, Langford CA. Harrison’s gastroenterology and hepatology 2nd ed. New York: McGraw Hill Education. 2013. pp 262-8.

Bruce MG, Maaroos HI (2008). Epidemiology of \textit{helicobacter pylori} infection. \textit{Helicobacter}, 12, 1-6.

Chen YI, Fallone CA (2015). A 14-day course of triple therapy is superior to a 10-day course for the eradication of \textit{Helicobacter pylori}: A canadian study conducted in a ‘real world’ setting. \textit{Can J Gastroenterol Hepatol}, 5, 7-10.

Chey WD, Leontiadis GI, Howden C, Moss SF (2017). ACG clinical guideline: treatment of \textit{helicobacter pylori} infection. \textit{Am J Gastroenterol}, 112, 212-38.

Chey WD, Wong BCY (2007). American college of gastroenterology guideline on the management of helicobacter pylori infection. \textit{Am J Gastroenterol}, 102, 1808-25.

Darnindro N, Syam AF, Fauzi A, Rumende C (2015). Seroprevalence and socio-demographic factors of \textit{helicobacter pylori} infection in patients with dyspepsia in Kaliabantu Primary Health Care North Jakarta. \textit{Acta Med Indones}, 47, 297-303.

Fennerty MB, Kovačs TOG, Krause R, et al (1998). A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of \textit{Helicobacter pylori}. \textit{Arch Intern Med}, 158, 1651-6.

Fock KM, Katerlais P, Sugano K, et al (2009). Second Asia-pacific consensus guidelines for \textit{helicobacter pylori} infection. \textit{JGHP}, 6, 1587-1600.

Goto Y, Syam AF, Darnindro N, Hapsari FCP (2016). Prevalence and risk factors for \textit{helicobacter pylori} infection among healthy inhabitants in northern Jakarta, Indonesia. \textit{Asian Pac J Cancer Prev}, 17, 4747-53.

Hunt RH, Xiao SD, Megraud F, et al (2010). World gastroenterology organization global guidelines \textit{Helicobacter pylori} in developing countries. \textit{World Gastroenterol Org}, 2010, 1-15.

Kawakubo H, Tanaka Y, Tsuruoka N, et al (2016). Upper gastrointestinal symptoms are more frequent in female than male young healthy Japanese volunteers as evaluated by questionnaire. \textit{J Neurogastroenterol Motil}, 22, 248-53.

Kusters JG, ven Vliet AHM, Kuipers EJ (2006). Pathogenesis of \textit{helicobacter pylori} infection. \textit{Clin Microbiol Rev}, 2006, 449-90.

Li BZ, Threapleton DE, Wang JY , et al (2015). Comparative effectiveness and tolerance of treatments for \textit{helicobacter pylori}: systematic review and networks meta-analysis. \textit{BMJ}, 351, 1-11.

Miftahussurur M, Syam AF, Nusi IA, et al (2016). Surveillance of \textit{helicobacter pylori} antibiotic susceptibility in Indonesia: different resistance types among regions and with novel genetic mutations. \textit{PLoS One}, 11, 1-17.

Suzuki T, Matsuo K, Ito H, et al (2016). Smoking increases the treatment failure for \textit{helicobacter pylori} eradication. \textit{Am J Med}, 119, 217-24.

Syam AF, Abdullah M, Rani AA, Nurdjanah S, Adi P Djumhana (2010). A comparison of 5 or 7 days of rabeprazole triple therapy for eradication of \textit{helicobacter pylori}. \textit{Med J Indones}, 2, 113-7.
Syam AF, Simadibrata M, Makmun D, et al (2017). National consensus on management of dyspepsia and helicobacter pylori infection. *Acta Med Indones.*, **49**, 279-87.

Yuan Y, Ford AC, Khan KJ, et al (2013). Optimum duration of regimens for *Helicobacter pylori* eradication. *Cochrane Database Syst Rev*, **2013**, 1-421.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.